Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis
Sponsor: FDA Office of Orphan Products Development
This PHASE1 trial investigates Respiratory Distress Syndrome and Respiratory Distress Syndrome, Adult and is currently completed. FDA Office of Orphan Products Development leads this study, which shows 6 recorded versions since 1998 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
First recorded
Sep 1998
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FDA Office of Orphan Products Development
- State University of New York
- Stony Brook University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Northport, United States
- • Stony Brook, United States